Oncology programThese trials will be somewhat de-risked because they are using chemo drugs that we know are effective in treating these various types of cancers. All they need to show is an improvement in treatment over the chemo drug alone. Which I think is very likely even just from a lowered dosage needed for the chemo drug stand point. The big hurdle in the trials will be the safety aspect and finding out how much excess chemo drug ends up in healthy tissues and organs due to the presence of sortilin receptors.